Based on our preclinical data and observations in CSF from LRRK2-PD patients, we explored the potential utility of BMP and GSLs as treatment-responsive biomarkers of LRRK2 inhibition in human subjects. The gene discussed is LRRK2; the disease is Parkinson disease.